Cemdisiran monotherapy, dosed subcutaneously every three months, met the primary and key secondary endpoints, showing a 2.3-point placebo-adjusted improvement in Myasthenia Gravis Activities of Daily ...

Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphoma showed 66% of Non-Hodgkin Lymphoma (NHL) patients achieving objective response rates, with 50% demonstrating ...

Drugmaker Eli Lilly says its daily oral GLP-1 pill may help people who have obesity and people with Type 2 diabetes lose ...

Investing.com -- Eli Lilly and Company (NYSE:LLY) stock rose in Tuesday premarket trading after the pharmaceutical giant ...

New data from Eli Lilly says its daily, oral GLP-1 pill may help people who have obesity and people who have Type 2 diabetes ...

Angamaly extension via Nedumbassery Airport is underway. The 17.5 km extension aims to enhance connectivity and improve ...

The proposed "Mahon Point 2.0" mixed use development will produce an monetary impact of €3.1 billion over a 25-year period, an economic impact study has estimated.

Phase 3 clinical trial results from Scripps Research and its collaborators supported FDA approval of ENCELTO, the first ...

Ecnoglutide, a novel once-weekly injection for type 2 diabetes management, works as well as dulaglutide (a commonly ...

Innovent's bispecific antibody, IBI363, enters a global phase 3 trial for IO-resistant lung cancer, the first of its kind, ...

In October 2024, Imuldosa received approval from the Food and Drug Administration based on data from the phase 3 Opportuniti ...

An announcement from Theravance Biopharma ( ($TBPH) ) is now available. On August 25, 2025, Theravance Biopharma announced the completion of ...